Michael A. Metzger is CEO at Syndax Pharmaceuticals Inc (SNDX). They have made 23 open-market trades across 3 companies since 2012, most recently 2026-07-08.
CIK 0001507220
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $2K since 2012, against 22 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SNDX | 484,843 | $6.3M |
| CTIC | 4,500 | $41K |
| RGDX | 1,000 | — |
| Total | $6.3M |
Shares reported on the most recent Form 4, priced at the 2026-07-09 close. 1 holding could not be priced and is excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SNDX | SELL · 10b5-1 | 2026-07-08 | 2026-07-09 | $24.24 | $785K | -8.5% | -17.6% | -31.1% |
| SNDX | SELL | 2026-06-01 | 2026-06-02 | $18.99 | $130K | -0.6% | +18.8% | +5.0% |
| SNDX | SELL | 2026-02-09 | 2026-02-10 | $21.03 | $361K | -6.8% | +12.3% | +0.0% |
| SNDX | SELL | 2026-02-06 | 2026-02-06 | $20.62 | $153K | -1.4% | +14.1% | -1.8% |
| SNDX | SELL · 10b5-1 | 2025-09-08 | 2025-09-08 | $16.41 | $5.2M | -4.3% | +2.2% | +23.7% |
| SNDX | SELL | 2025-07-16 | 2025-07-18 | $9.29 | $140K | +5.0% | +66.9% | +58.3% |
| SNDX | SELL · 10b5-1 | 2025-03-04 | 2025-03-06 | $15.05 | $235K | -11.2% | -22.5% | -22.8% |
| SNDX | SELL | 2025-02-10 | 2025-02-12 | $15.50 | $206K | +3.1% | -12.4% | -31.0% |
| SNDX | SELL | 2023-02-06 | 2023-02-08 | $27.64 | $329K | -0.9% | -14.1% | -16.5% |
| CTIC | SELL | 2022-11-08 | 2022-11-10 | $5.58 | $997K | +0.8% | -1.5% | -9.9% |
| SNDX | SELL | 2022-10-06 | 2022-10-07 | $25.29 | $821K | -8.0% | -5.8% | +2.1% |
| SNDX | SELL | 2022-09-30 | 2022-10-04 | $25.02 | $1.7M | -5.1% | -10.0% | +3.2% |
| SNDX | SELL | 2022-07-25 | 2022-07-27 | $21.06 | $1.3M | +13.2% | +7.5% | +8.3% |
| CTIC | SELL | 2022-07-07 | 2022-07-11 | $6.51 | $131K | -6.8% | -8.7% | -22.5% |
| SNDX | SELL | 2022-07-06 | 2022-07-08 | $21.07 | $635K | -0.3% | +26.7% | +36.9% |
| CTIC | SELL | 2022-07-05 | 2022-07-07 | $6.07 | $1.1M | -8.8% | -0.1% | -16.5% |
| SNDX | SELL | 2021-12-16 | 2021-12-20 | $19.76 | $2.1M | +2.8% | -22.4% | -20.4% |
| SNDX | SELL | 2021-12-13 | 2021-12-15 | $19.05 | $1.4M | +17.4% | -0.8% | -11.8% |
| SNDX | SELL | 2021-10-25 | 2021-10-27 | $19.15 | $2.3M | -5.8% | -11.3% | -11.5% |
| SNDX | SELL | 2021-09-27 | 2021-09-28 | $19.51 | $954K | -7.8% | -2.4% | +12.4% |
| SNDX | SELL | 2021-09-20 | 2021-09-22 | $19.23 | $1.4M | +1.0% | +0.6% | +12.8% |
| SNDX | SELL | 2021-09-13 | 2021-09-15 | $19.11 | $2.3M | +1.9% | -4.1% | -8.3% |
| SNDX | SELL | 2021-02-01 | 2021-02-03 | $20.19 | $303K | +0.7% | +11.7% | -28.7% |
| SNDX | SELL | 2020-12-01 | 2020-12-03 | $22.97 | $345K | +7.2% | -8.1% | -8.7% |
| SNDX | SELL | 2020-11-04 | 2020-11-06 | $20.31 | $4.1M | +6.2% | +20.6% | -4.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.